Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Trazodone Once a Day in Major Depression Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02086929
Recruitment Status : Completed
First Posted : March 13, 2014
Last Update Posted : December 30, 2015
Sponsor:
Information provided by (Responsible Party):
Aziende Chimiche Riunite Angelini Francesco S.p.A

Tracking Information
First Submitted Date  ICMJE March 12, 2014
First Posted Date  ICMJE March 13, 2014
Last Update Posted Date December 30, 2015
Study Start Date  ICMJE December 2012
Actual Primary Completion Date April 2014   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 12, 2014)
Hamilton Depression Rating Scale (HAMD) score [ Time Frame: Day 56 ]
Mean change from baseline (Day 0) in HAMD score at Day 56.
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT02086929 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: March 12, 2014)
  • Montgomery-Asberg Depression Rating Scale (MADRS) score [ Time Frame: Day 56 ]
    Mean change from baseline (Day 0) in MADRS score at Day 56.
  • Clinical Global Impression (CGI) Severity of Illness score [ Time Frame: Day 56 ]
    CGI-Severity of Illness improvement at Day 56.
  • Clinical Global Impression (CGI) Global improvement score [ Time Frame: Day 56 ]
    CGI-Global improvement at Day 56.
  • Percentage of responders [ Time Frame: Day 56 ]
    Rate of patients with a 50% decrease with respect to baseline on the HAMD score at Day 56.
  • Percentage of patients with remission [ Time Frame: Day 56 ]
    Rate of patients with a HAMD score <or= at Day 56.
  • Safety profile of trazodone OAD compared to venlafaxine XR [ Time Frame: 11 weeks ]
    Safety and tolerability will be assessed through adverse events monitoring, physical examinations and monitoring of vital signs, body weight, clinical laboratory tests, ECG.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Trazodone Once a Day in Major Depression Disorder
Official Title  ICMJE A Randomized, Double-blind Study Comparing the Efficacy and Safety of Trazodone OAD and Venlafaxine XR in the Treatment of Patients With Major Depressive Disorder.
Brief Summary The study objective is to evaluate the efficacy and safety of trazodone OAD vs venlafaxine extended release (venlafaxine XR) after an 8-week treatment period in patients with major depressive disorder.
Detailed Description This randomized, venlafaxine-controlled, double-blind, parallel design study consists of a Pre-Treatment Phase (screening, wash-out) and a double-blind Treatment Phase (randomization to trazodone OAD or to venlafaxine XR, treatment for 8 weeks and tapering for 1 to 3 weeks). During the Pre-Treatment Phase, patients who sign an informed consent form will undergo initial screening. Potential candidates will be instructed to discontinue antidepressants or prohibited medications (wash-out) for a period specific to taper schedule (based on 5 elimination half-lives of the used medication). On the last day of the Pre-Treatment Phase, patients will be evaluated for the final eligibility, and those qualified will be randomly allocated in a 1:1 proportion to trazodone OAD 300 mg/day (1 week of tapering with trazodone OAD 150 mg/day) or to venlafaxine XR 75 mg/day once daily. After 3 and 5 weeks of treatment, subjects will be evaluated for the response. For non responding patients dose increases (in increments of 75 mg/day) will be done till to reach the maximum of 225 mg/day for venlafaxine XR and 450 mg/day for trazodone OAD. Patients non responding to treatment at the final visit will have their study medication tapered from 1 to 3 weeks, according to the maximum dose reached during the study. In order to prevent relapse of depression symptoms, responders at the final visit may continue the treatment. In this case, an unblinded third party Dispenser will open the treatment code and will prescribe the same medication taken by the patients during the trial, according to the formulation available on the market.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Major Depressive Disorder
Intervention  ICMJE
  • Drug: Trazodone
  • Drug: Venlafaxine
Study Arms  ICMJE
  • Experimental: Trazodone

    300 mg/day for 8 weeks (including 1 week 150 mg/day of dose-titration). After 3 and 5 weeks of treatment, non responders will have dose increases (in increments of 75 mg/day) till to reach the maximum of 450 mg/day.

    Dosage form: capsule.

    Intervention: Drug: Trazodone
  • Active Comparator: Venlafaxine XR

    75 mg/die for 8 weeks. After 3 and 5 weeks of treatment, non responders will have dose increases (in increments of 75 mg/day) till to reach the maximum of 225 mg/day.

    Dosage form: capsule.

    Intervention: Drug: Venlafaxine
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: December 29, 2015)
364
Original Estimated Enrollment  ICMJE
 (submitted: March 12, 2014)
360
Actual Study Completion Date  ICMJE April 2014
Actual Primary Completion Date April 2014   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • men and women 18-75 years of age (limits included) with no limitation of race;
  • outpatients;
  • major depressive disorder according to DSM-IV criteria as assessed using the MINI International Neuropsychiatric Interview;
  • 17-item HAMD score > 18 at both screening and baseline visits with a decrease not exceeding 20% between screening and baseline;
  • symptoms of depression for at least one month before study entry (screening visit);
  • legally capable to give their consent to participate the study, and available to sign and date the written informed consent prior to the inclusion in the study;
  • women of childbearing potential must agree not to start a pregnancy from the signature of the informed consent up to 30 days after the last administration of the investigational product.

Exclusion Criteria:

  • participation in another trial involving any investigational drug during the past 60 days;
  • known hypersensitivity to venlafaxine or trazodone or their excipients;
  • use of venlafaxine or trazodone within the previous six months;
  • acute, or chronic, or recurrent medical conditions that might affect/jeopardize the study results;
  • significant liver disease, defined as active hepatitis or elevated liver enzymes > 3 times the upper boundary of the normal range;
  • significant renal disease, defined as urea and/or creatinine > 3 times the upper boundary of the normal range
  • myocardial infarction within 6 months prior to start of the double blind treatment;
  • positive present history of glaucoma;
  • history of risk factors for Torsade de Pointes, such as heart failure, cardiac arrhythmias, bradycardia, cardiac conduction abnormalities, family history of long QT syndrome, cardiac hypertrophy, cardiomyopathy, chronic cardiac insufficiency;
  • values of electrolytes (sodium, potassium, calcium, magnesium, chloride) outside the normal laboratory range and judged clinically relevant by the Investigator;
  • concomitant treatment with drugs known for QT prolongation, or with drugs producing hypokalemia, or diuretics;
  • QTcF values higher than 450 msec in the ECG performed at the screening;
  • history of major depression resistant to medical treatments (previous failure to respond to two consecutive antidepressants of different classes used for a sufficient length of time at appropriate doses);
  • history of seizure events other than a single childhood febrile seizure;
  • history of alcohol or psychoactive substance abuse or addiction (except caffeine or nicotine) during the last year as defined by DSM-IV criteria;
  • positive urine drug screen for CNS-active drugs (cocaine, opioids, amphetamines and cannabinoids) at Visit 1 (screening);
  • acute risk of suicide (HAMD, criterion 3 with a value > 3);
  • presence of any primary psychiatric disorder other than major depression;
  • history or presence of bipolar disorder, any psychotic disorder, mental disorder due to general medical conditions;
  • pregnancy, lactation, or female with a positive urine pregnancy test result at Visit 1 (Screening);
  • electroconvulsive therapy (ECT) within 30 days prior to the screening visit;
  • use of antipsychotic drugs within two months prior to the baseline visit (Visit 2);
  • use of any anxiolytic or sedative hypnotic drug within seven days prior to the baseline (Visit 2) and during the study. Exception is stable low doses of benzodiazepines for insomnia (if taken by the patient more than two weeks before the Treatment Phase);
  • use of any psychotropic drug or substance with central nervous system effects within seven days prior to the baseline visit (Visit 2);
  • use of any non-psychotropic drug with psychotropic effects (e.g. alpha-adrenergic blockers) within seven days prior to the baseline visit (visit 2), unless a stable dose of the drug has been maintained for at least one month (three months for thyroid or hormonal medications) before the baseline visit (visit 2);
  • concomitant treatment with CYP3A4 inhibitors (e.g. ketoconazole, ritonavir, indinavir);
  • hyperthyroidism, even if pharmacologically corrected;
  • start or discontinuation of psychotherapy within 6 weeks prior to screening;
  • clinically significant abnormalities on physical examination, vital signs, ECG, laboratory tests at the screening visit;
  • high blood pressure (supine systolic blood pressure > 160 mmHg or supine diastolic blood pressure > 90 mmHg) at screening or baseline, either untreated or under treatment with antihypertensives
  • inability to comply with the protocol requirements, instructions and study-related restrictions; e.g. uncooperative attitude, inability to return for study-visits, and improbability of completing the clinical study;
  • vulnerable subjects (e.g. persons kept in detention);
  • if subject is the Investigator or his/her deputies, first grade relative, research assistant, pharmacist, study coordinator, other staff of relative thereof directly involved in the conduct of the study.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Spain,   Austria,   Czech Republic,   Italy,   Romania,   Slovakia
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02086929
Other Study ID Numbers  ICMJE 039(C)SC11063
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Aziende Chimiche Riunite Angelini Francesco S.p.A
Study Sponsor  ICMJE Aziende Chimiche Riunite Angelini Francesco S.p.A
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Filippo Bogetto, MD Department of Neuroscience University of Turin - Italy
PRS Account Aziende Chimiche Riunite Angelini Francesco S.p.A
Verification Date December 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP